Please assess the completion status of the following clinical trial:

Trial Title: Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with LBD who completed a previous nelotanserin VH or RBD study~Exclusion Criteria:~* Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid, gastrointestinal, renal, hematologic or other medical disorder

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nelotanserin (Type: EXPERIMENTAL): Once Daily, Oral, at 20, 40, 60, or 80 mg dose

Based on this trial design, predict the completion outcome and termination type (if applicable).